Patients with type 2 leprosy reactions demonstrate notably reduced circulating and in situ quantities. Tregs were compared to both type 1 leprosy reaction patients and the control group. The observed decline was accompanied by a concurrent rise in interleukin-17 (IL-17) expression within the local environment while transforming growth factor-beta (TGF-β) expression experienced a decline. Here, IL17A is linked to leprosy.